Turing CEO Concedes, Will Lower Daraprim Price

Sep 24, 2015

After the internet exploded with hatred for Turing Pharmaceuticals CEO Martin Shkreli following his 5000% price increase for toxoplasmosis drug Daraprim, Shkreli now says Turing will make the drug more affordable.

“We’ve agreed to lower the price of Daraprim to a point that is more affordable and it’s able to allow the company to make a profit, a very small profit,” said Shkreli.

Daraprim is used to treat toxoplasmosis, a parasitic disease that affects people with weakened immune systems, such as those with AIDS or cancer. Turing acquired Daraprim in August, and immediately raised the price from $13.50 a tablet to $750 a tablet.

There is no word on what the new, lower price will be. Shkreli warned that lowering the drug price will likely mean that Turing will have to cut back on R&D spending and/or layoff employees.

The Turing controversy arrives at a time of growing concern over the rising prices of drugs. Several politicians have responded by proposing plans to lower the price of prescription drugs.

Read the
USA Today article

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments